1.555
前日終値:
$1.58
開ける:
$1.57
24時間の取引高:
43,578
Relative Volume:
0.12
時価総額:
$160.08M
収益:
-
当期純損益:
$-13.73M
株価収益率:
-11.96
EPS:
-0.13
ネットキャッシュフロー:
$-3.92M
1週間 パフォーマンス:
-1.58%
1か月 パフォーマンス:
+14.34%
6か月 パフォーマンス:
+123.36%
1年 パフォーマンス:
+75.59%
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
TLSA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TLSA
Tiziana Life Sciences Ltd
|
1.55 | 160.08M | 0 | -13.73M | -3.92M | -0.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
453.71 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
541.42 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
319.34 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
561.96 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
240.76 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2020-12-22 | 開始されました | B. Riley Securities | Buy |
2018-12-17 | 開始されました | Laidlaw | Buy |
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Promising Penny Stocks To Consider In June 2025 - simplywall.st
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting (NASDAQ:TLSA) - Seeking Alpha
Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis - MarketScreener
Small cap wrap: Tiziana Life Sciences, Challenger Energy, Arrow Exploration... - Proactive financial news
Tiziana expands Phase 2 MS trial to fifth site, commences patient dosing - Proactive financial news
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - The Manila Times
Breakthrough Multiple Sclerosis Treatment Enters Next Phase as Weill Cornell Joins Major Clinical Trial - Stock Titan
Market movers: RH, Tiziana, Archer Aviation... - Proactive Investors
Shares of Tiziana Life Sciences (TLSA) Climb on CEO's Upcoming P - GuruFocus
Tiziana shares rise on presentation date for foralumab data - Seeking Alpha
Tiziana CEO to present clinical advances of intranasal foralumab at BIO 2025 - Proactive financial news
Tiziana Life Sciences to Present at the Bio International Convention - The Manila Times
Revolutionary Intranasal Treatment for MS and Alzheimer's: Tiziana CEO Reveals Latest Clinical Findings at BIO 2025 - Stock Titan
Tiziana Life Sciences Ltd (TLSA) Stock: A Comprehensive 52-Week Review - investchronicle.com
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% – Still a Buy? - Defense World
TLSA Advances Alzheimer's Treatment with Innovative Nasal Spray - GuruFocus
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease - marketscreener.com
Tiziana Life Sciences Announces Interview Highlighting Intranasa - GuruFocus
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease | TLSA Stock News - GuruFocus
Tiziana Life Sciences Announces Breakthrough Advancement in Moderate Alzheimer’s Treatment with Intranasal Foralumab - Nasdaq
Breakthrough: First Alzheimer's Patient Shows Improvement with Revolutionary Nasal Antibody Treatment - Stock Titan
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - BioSpace
Small cap wrap: Lancaster Resources, Cerro de Pasco, Tiziana Life Sciences, Nano One Materials... - Proactive financial news
Tiziana reports reduction in microglial activation in Alzheimer’s case treated with nasal foralumab - Proactive financial news
TLSA: Tiziana Life Sciences Study Shows Promise for Alzheimer's Treatment | TLSA Stock News - GuruFocus
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - The Manila Times
Journal Of Clinical Nuclear Medicine Publishes Results Of Tiziana’S Nasal Foralumab In Study Treating Moderate Alzheimer's Disease - MENAFN.com
Journal of Clinical Nuclear Medicine Publishes Results of - GlobeNewswire
Revolutionary Nasal Treatment Reduces Brain Inflammation in Moderate Alzheimer's Patient, Harvard Study Shows - Stock Titan
Tiziana Life Sciences chairman increases stake to over 37% - Proactive financial news
Executive Chairman Increases Stake in Tiziana Life Sciences (TLS - GuruFocus
Tiziana Life Sciences Announces Purchase of Shares by Chairman - The Manila Times
Tiziana reports promising Alzheimer’s treatment results By Investing.com - Investing.com Nigeria
Tiziana reports promising Alzheimer’s treatment results - Investing.com
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab - BioSpace
Tiziana Reports PET data sees reduced neuroinflammation in patient treated with Intranasal Therapy - Proactive Investors
Market movers: Lyft, US Gold, Tiziana Life Sciences... - Proactive Investors
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer’s patient treated with nasal foralumab - Proactive Investors
TLSA: Tiziana Life Sciences Reports Positive PET Scan Results in Alzheimer's Treatment | TLSA Stock News - GuruFocus
Tiziana stock gains on data for Alzheimer's drug (TLSA:NASDAQ) - Seeking Alpha
Tiziana Life Sciences Announces Significant Reduction In Microglia Activation In PET Scan Of Moderate Alzheimer's Patient Treated With Intranasal Foralumab - MENAFN.com
Tiziana Life Sciences Announces Significant Reduction in - GlobeNewswire
Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study - PMLiVE
Small cap wrap: Tiziana Life Sciences, Millennial Potash, Century LIthium... - Proactive financial news
Tiziana shares surge 21% on promising multiple sclerosis data - Proactive financial news
Tiziana rises on positive results in multiple sclerosis treatment study - Seeking Alpha
Tiziana reports encouraging results for nasal MS drug in early study - Proactive Investors
TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLS - GuruFocus
TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLSA Stock News - GuruFocus
Clinical Trial Success: Revolutionary Nasal Spray Halts Multiple Sclerosis Progression in Landmark Study - Stock Titan
Tiziana Life Sciences Ltd (TLSA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):